1. Home
  2. CNVS vs BTAI Comparison

CNVS vs BTAI Comparison

Compare CNVS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cineverse Corp.

CNVS

Cineverse Corp.

HOLD

Current Price

$3.01

Market Cap

65.5M

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

35.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNVS
BTAI
Founded
2000
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.5M
35.6M
IPO Year
2016
2018

Fundamental Metrics

Financial Performance
Metric
CNVS
BTAI
Price
$3.01
$1.66
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$9.00
$26.67
AVG Volume (30 Days)
449.5K
285.4K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
108.99
N/A
EPS
N/A
N/A
Revenue
$78,181,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$84.42
$261.81
P/E Ratio
N/A
N/A
Revenue Growth
59.13
N/A
52 Week Low
$1.77
$1.17
52 Week High
$7.39
$8.08

Technical Indicators

Market Signals
Indicator
CNVS
BTAI
Relative Strength Index (RSI) 64.70 50.49
Support Level $2.37 $1.50
Resistance Level $3.49 $1.72
Average True Range (ATR) 0.30 0.10
MACD 0.03 0.01
Stochastic Oscillator 74.40 50.94

Price Performance

Historical Comparison
CNVS
BTAI

About CNVS Cineverse Corp.

Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: